Evidence map›Paper›PMID 36341425›Full record

Trial reportFrontiers in immunology2022

Humoral and cellular immune responses to CoronaVac up to one year after vaccination.

Priscilla Ramos Costa, Carolina Argondizo Correia, Mariana Prado Marmorato, Juliana Zanatta de Carvalho Dias, Mateus Vailant Thomazella, Amanda Cabral da Silva, Ana Carolina Soares de Oliveira, Arianne Fagotti Gusmão, Lilian Ferrari, Angela Carvalho Freitas and 7 more

Open access · goldAbstract readClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. The characterization of CD8Emerging microbes & infections · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Priscilla Ramos CostaMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil.
Carolina Argondizo CorreiaMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil.
Mariana Prado MarmoratoMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil.
Juliana Zanatta de Carvalho DiasMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil.
Mateus Vailant ThomazellaMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil.
Amanda Cabral da SilvaMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil.
Ana Carolina Soares de OliveiraMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil.
Arianne Fagotti GusmãoMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil.
Lilian FerrariMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil.
Angela Carvalho FreitasDepartment of Infectious and Parasitic Diseases, Clinicas Hospital, School of Medicine, University of São Paulo, São Paulo, Brazil.
Elizabeth González PatiñoCenter for Clinical Trials and Pharmacovigilance Butantan Institute, São Paulo, Brazil.
Alba GrifoniCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, San Diego, CA, United States.
Daniela WeiskopfCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, San Diego, CA, United States.
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, San Diego, CA, United States.
Rami ScharfPATH, Washington, DC, United States.
Esper Georges KallásMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil.
Cássia Gisele Terrassani SilveiraMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil.
Universidade de São Paulo · BRLa Jolla Institute for Immunology · USHospital de Clínicas de Porto Alegre · BRInstituto Butantan · BRProgram for Appropriate Technology in Health · US

Funding

Large Scale T Cell Epitope Discovery:Global identification of epitopes derived from Zika (ZIKV), Chikungunya (CHIKV) viruses following natural infection and vaccination75N93019C00065 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI MITCHELL, MAYA · 2019 to 2023
$7.3M
Bill & Melinda Gates Foundation INV-021239NIAID NIH HHS 75N93019C00065
6 · The paper itself

Abstract

Coronavac is a widely used SARS-CoV-2 inactivated vaccine, but its long-term immune response assessment is still lacking. We evaluated SARS-CoV-2-specific immune responses, including T cell activation markers, antigen-specific cytokine production and antibody response following vaccination in 53 adult and elderly individuals participating in a phase 3 clinical trial. Activated follicular helper T (Tfh), non-Tfh and memory CD4

Indexed as

COVID-19COVID-19 VaccinesAntibodies, ViralCytokinesHumansImmunity, CellularImmunoglobulin GSARS-CoV-2VaccinationAntibodies, ViralCOVID-19 VaccinesCytokinesImmunoglobulin Gcellular responseCoronaVachumoral responseimmune memoryvaccination

Identifiers

PMID36341425
PMCPMC9634255
OpenAlexW4306968936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.